Registration and Regulation Committee

Adopted in House Comm. on Nov 15, 2006

 

 


 

 


 
09400SB2427ham001 LRB094 17702 RLC 60453 a

1
AMENDMENT TO SENATE BILL 2427

2     AMENDMENT NO. ______. Amend Senate Bill 2427 by replacing
3 everything after the enacting clause with the following:
 
4     "Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 201, 206, and 218 as follows:
 
6     (720 ILCS 570/201)  (from Ch. 56 1/2, par. 1201)
7     Sec. 201. (a) The Department shall carry out the provisions
8 of this Article. The Department or its successor agency may add
9 substances to or delete or reschedule all controlled substances
10 in the Schedules of Sections 204, 206, 208, 210 and 212 of this
11 Act. In making a determination regarding the addition,
12 deletion, or rescheduling of a substance, the Department shall
13 consider the following:
14         (1) the actual or relative potential for abuse;
15         (2) the scientific evidence of its pharmacological
16     effect, if known;
17         (3) the state of current scientific knowledge
18     regarding the substance;
19         (4) the history and current pattern of abuse;
20         (5) the scope, duration, and significance of abuse;
21         (6) the risk to the public health;
22         (7) the potential of the substance to produce
23     psychological or physiological dependence;
24         (8) whether the substance is an immediate precursor of

 

 

09400SB2427ham001 - 2 - LRB094 17702 RLC 60453 a

1     a substance already controlled under this Article;
2         (9) the immediate harmful effect in terms of
3     potentially fatal dosage; and
4         (10) the long-range effects in terms of permanent
5     health impairment.
6     (b) (Blank).
7     (c) (Blank).
8     (d) If any substance is scheduled, rescheduled, or deleted
9 as a controlled substance under Federal law and notice thereof
10 is given to the Department, the Department shall similarly
11 control the substance under this Act after the expiration of 30
12 days from publication in the Federal Register of a final order
13 scheduling a substance as a controlled substance or
14 rescheduling or deleting a substance, unless within that 30 day
15 period the Department objects, or a party adversely affected
16 files with the Department substantial written objections
17 objecting to inclusion, rescheduling, or deletion. In that
18 case, the Department shall publish the reasons for objection or
19 the substantial written objections and afford all interested
20 parties an opportunity to be heard. At the conclusion of the
21 hearing, the Department shall publish its decision, by means of
22 a rule, which shall be final unless altered by statute. Upon
23 publication of objections by the Department, similar control
24 under this Act whether by inclusion, rescheduling or deletion
25 is stayed until the Department publishes its ruling.
26     (e) The Department shall by rule exclude any non-narcotic
27 substances from a schedule if such substance may, under the
28 Federal Food, Drug, and Cosmetic Act, be lawfully sold over the
29 counter without a prescription.
30     (f) (Blank) The sale, delivery, distribution, and
31 possession of a drug product containing dextromethorphan shall
32 be in accordance with Section 218 of this Act..
33     (g) Authority to control under this section does not extend
34 to distilled spirits, wine, malt beverages, or tobacco as those

 

 

09400SB2427ham001 - 3 - LRB094 17702 RLC 60453 a

1 terms are defined or used in the Liquor Control Act and the
2 Tobacco Products Tax Act.
3     (h) Persons registered with the Drug Enforcement
4 Administration to manufacture or distribute controlled
5 substances shall maintain adequate security and provide
6 effective controls and procedures to guard against theft and
7 diversion, but shall not otherwise be required to meet the
8 physical security control requirements (such as cage or vault)
9 for Schedule V controlled substances containing
10 pseudoephedrine or Schedule II controlled substances
11 containing dextromethorphan.
12 (Source: P.A. 94-800, eff. 1-1-07; revised 8-3-06.)
 
13     (720 ILCS 570/206)  (from Ch. 56 1/2, par. 1206)
14     Sec. 206. (a) The controlled substances listed in this
15 Section are included in Schedule II.
16     (b) Unless specifically excepted or unless listed in
17 another schedule, any of the following substances whether
18 produced directly or indirectly by extraction from substances
19 of vegetable origin, or independently by means of chemical
20 synthesis, or by combination of extraction and chemical
21 synthesis:
22         (1) Opium and opiates, and any salt, compound,
23     derivative or preparation of opium or opiate, excluding
24     apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
25     nalmefene, naloxone, and naltrexone, and their respective
26     salts, but including the following:
27             (i) Raw Opium;
28             (ii) Opium extracts;
29             (iii) Opium fluid extracts;
30             (iv) Powdered opium;
31             (v) Granulated opium;
32             (vi) Tincture of opium;
33             (vii) Codeine;

 

 

09400SB2427ham001 - 4 - LRB094 17702 RLC 60453 a

1             (viii) Ethylmorphine;
2             (ix) Etorphine Hydrochloride;
3             (x) Hydrocodone;
4             (xi) Hydromorphone;
5             (xii) Metopon;
6             (xiii) Morphine;
7             (xiv) Oxycodone;
8             (xv) Oxymorphone;
9             (xvi) Thebaine;
10             (xvii) Thebaine-derived butorphanol.
11             (xviii) Dextromethorphan, except drug products
12         that may be dispensed pursuant to a prescription order
13         of a practitioner and are sold in compliance with the
14         safety and labeling standards as set forth by the
15         United States Food and Drug Administration, or drug
16         products containing dextromethorphan that are sold in
17         solid, tablet, liquid, capsule, powder, thin film, or
18         gel form and which are formulated, packaged, and sold
19         in dosages and concentrations for use as an
20         over-the-counter drug product. For the purposes of
21         this Section, "over-the-counter drug product" means a
22         drug that is available to consumers without a
23         prescription and sold in compliance with the safety and
24         labeling standards as set forth by the United States
25         Food and Drug Administration subject to Section 218 of
26         this Act.
27         (2) Any salt, compound, isomer, derivative or
28     preparation thereof which is chemically equivalent or
29     identical with any of the substances referred to in
30     subparagraph (1), but not including the isoquinoline
31     alkaloids of opium;
32         (3) Opium poppy and poppy straw;
33         (4) Coca leaves and any salt, compound, isomer, salt of
34     an isomer, derivative, or preparation of coca leaves

 

 

09400SB2427ham001 - 5 - LRB094 17702 RLC 60453 a

1     including cocaine or ecgonine, and any salt, compound,
2     isomer, derivative, or preparation thereof which is
3     chemically equivalent or identical with any of these
4     substances, but not including decocainized coca leaves or
5     extractions of coca leaves which do not contain cocaine or
6     ecgonine (for the purpose of this paragraph, the term
7     "isomer" includes optical, positional and geometric
8     isomers);
9         (5) Concentrate of poppy straw (the crude extract of
10     poppy straw in either liquid, solid or powder form which
11     contains the phenanthrine alkaloids of the opium poppy).
12     (c) Unless specifically excepted or unless listed in
13 another schedule any of the following opiates, including their
14 isomers, esters, ethers, salts, and salts of isomers, whenever
15 the existence of these isomers, esters, ethers and salts is
16 possible within the specific chemical designation, dextrorphan
17 excepted:
18         (1) Alfentanil;
19         (1.1) Carfentanil;
20         (2) Alphaprodine;
21         (3) Anileridine;
22         (4) Bezitramide;
23         (5) Bulk Dextropropoxyphene (non-dosage forms);
24         (6) Dihydrocodeine;
25         (7) Diphenoxylate;
26         (8) Fentanyl;
27         (9) Sufentanil;
28         (9.5) Remifentanil;
29         (10) Isomethadone;
30         (11) Levomethorphan;
31         (12) Levorphanol (Levorphan);
32         (13) Metazocine;
33         (14) Methadone;
34         (15) Methadone-Intermediate,

 

 

09400SB2427ham001 - 6 - LRB094 17702 RLC 60453 a

1     4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
2         (16) Moramide-Intermediate,
3     2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
4     acid;
5         (17) Pethidine (meperidine);
6         (18) Pethidine-Intermediate-A,
7     4-cyano-1-methyl-4-phenylpiperidine;
8         (19) Pethidine-Intermediate-B,
9     ethyl-4-phenylpiperidine-4-carboxylate;
10         (20) Pethidine-Intermediate-C,
11     1-methyl-4-phenylpiperidine-4-carboxylic acid;
12         (21) Phenazocine;
13         (22) Piminodine;
14         (23) Racemethorphan;
15         (24) Racemorphan;
16         (25) Levo-alphacetylmethadol (some other names:
17     levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
18     (d) Unless specifically excepted or unless listed in
19 another schedule, any material, compound, mixture, or
20 preparation which contains any quantity of the following
21 substances having a stimulant effect on the central nervous
22 system:
23         (1) Amphetamine, its salts, optical isomers, and salts
24     of its optical isomers;
25         (2) Methamphetamine, its salts, isomers, and salts of
26     its isomers;
27         (3) Phenmetrazine and its salts;
28         (4) Methylphenidate.
29     (e) Unless specifically excepted or unless listed in
30 another schedule, any material, compound, mixture, or
31 preparation which contains any quantity of the following
32 substances having a depressant effect on the central nervous
33 system, including its salts, isomers, and salts of isomers
34 whenever the existence of such salts, isomers, and salts of

 

 

09400SB2427ham001 - 7 - LRB094 17702 RLC 60453 a

1 isomers is possible within the specific chemical designation:
2         (1) Amobarbital;
3         (2) Secobarbital;
4         (3) Pentobarbital;
5         (4) Pentazocine;
6         (5) Phencyclidine;
7         (6) Gluthethimide;
8         (7) (Blank).
9     (f) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances:
13         (1) Immediate precursor to amphetamine and
14     methamphetamine:
15             (i) Phenylacetone
16         Some trade or other names: phenyl-2-propanone;
17         P2P; benzyl methyl ketone; methyl benzyl ketone.
18         (2) Immediate precursors to phencyclidine:
19             (i) 1-phenylcyclohexylamine;
20             (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
21         (3) Nabilone.
22 (Source: P.A. 94-800, eff. 1-1-07.)
 
23     (720 ILCS 570/218)
24     Sec. 218. Dextromethorphan.
25     (a) (Blank) A drug product containing dextromethorphan may
26 not be sold, delivered, distributed, or possessed except in
27 accordance with the prescription requirements of Sections 309,
28 312, and 313 of this Act.
29     (b) Possession of a drug product containing
30 dextromethorphan in violation of this Act Section is a Class 4
31 felony. The sale, delivery, distribution, or possession with
32 intent to sell, deliver, or distribute a drug product
33 containing dextromethorphan in violation of this Act Section is

 

 

09400SB2427ham001 - 8 - LRB094 17702 RLC 60453 a

1 a Class 2 felony.
2     (c) (Blank) This Section does not apply to a drug product
3 containing dextromethorphan that is sold in solid, tablet,
4 liquid, capsule, powder, thin film, or gel form and which is
5 formulated, packaged, and sold in dosages and concentrations
6 for use as an over-the-counter drug product. For the purposes
7 of this Section, "over-the-counter drug product" means a drug
8 that is available to consumers without a prescription and sold
9 in compliance with the safety and labeling standards as set
10 forth by the United States Food and Drug Administration.
11 (Source: P.A. 94-800, eff. 1-1-07.)
 
12     Section 99. Effective date. This Act takes effect upon
13 becoming law.".